Victoza® to be evaluated in paediatric type 2 diabetes population
In response to Authority requests to document the safety and efficacy of liraglutide (Victoza®) in children and adolescents with type 2 diabetes, Novo Nordisk has initiated a global clinical trial named "Ellipse" or NN2211-3659. To learn more about the trial, the participating countries and where to get more information, please follow the links below.
Novo Nordisk pipeline news
In a Company Announcement on 19th December 2012, Novo Nordisk reported three significant pipeline developments:
Novo Nordisk ranks 4th among the world’s top 20 science employers
Bagsværd, Denmark - Novo Nordisk was ranked number four on the Science 2012 Top Employer list – up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.